

Epidemiology

- Highly contagious. It is arguably the most contagious disease in existence
- Transmission is **airborne**, by respiratory droplets, or by contact with secretions

Incubation Period

- Usually 8-12 days. Average time between exposure and subsequent cases is 14 days, with a range of 7-18 days.

Clinical Presentation

- Prodrome (usually 2-4 days) of stepwise increasing fever (often reaching 103°-105°F), cough, coryza, and/or conjunctivitis (the "3 C's")
- Koplik's spots (small bluish white spots on an erythematous base) on buccal mucosa sometimes seen 1-2 days before rash are pathognomonic
- Maculopapular rash begins at hairline, then face and upper neck, then proceeds downward and outward, reaching hands and feet
- During an outbreak, a probable case is generally defined as:
 - Generalized rash lasting >3 days, and
 - Temperature >38.3°C (101°F), and
 - Cough, coryza or conjunctivitis
- Other symptoms may include anorexia, diarrhea (especially in infants), and generalized lymphadenopathy

Variations

- Atypical measles – in persons who previously received inactivated ("killed") measles vaccine, given in the U.S. from 1963 through 1967 – fever, pneumonia, pleural effusions and edema
- Modified measles – in persons who received IG as prophylaxis, in infants who have some maternal antibody, or in previously vaccinated persons – prolonged incubation period, mild prodrome, sparse rash of short duration
- In immunocompromised persons, disease may be severe and prolonged without typical rash

Differential Diagnosis

- Rubella, scarlet fever, drug rashes, serum sickness, roseola infantum, infectious mononucleosis, adenovirus, echovirus, and coxsackievirus

Laboratory

- IgM capture serology (but 20% false negative during first 72 hrs of rash)
- Alternatively, acute and convalescent paired IgG serology 10-30 days apart
- Testing is available at the Arizona State Public Health Lab - arrange testing through your local health department

Infection control

- For patients in the hospital, **airborne** precautions from onset of the prodrome (cough, coryza, conjunctivitis) through the 4th day of rash
- For nonimmune health care personnel, exclusion from direct patient care from 5th to 21st day after exposure.

Treatment

- Supportive care plus Vitamin A supplementation: two doses one day apart, plus a third dose 2-4 weeks later if signs of Vitamin A deficiency:
 - < 6 m.o. – 50,000 IU / dose
 - 6-11 m.o. – 100,000 IU / dose
 - ≥ 12 m.o. – 200,000 IU / dose

Prophylaxis

- Determine immune status of all those exposed
 - Adults born before 1957 are generally presumed to be immune from prior disease (but vaccine may be given if unsure)
 - Complete vaccination is two doses of live virus vaccine, at least 28 days apart, with the first dose given at 12 months of age or older (>99% efficacy)
- If susceptible, vaccinate with MMR **within 72 hrs of exposure**
- Alternatively, if unable to vaccinate (e.g., infants less than 12 mo of age), immune globulin (IG) (0.25mL/kg body weight), maximum 15 mL given IM (if immunocompromised, 0.5mL/kg, maximum 15 mL), administered **within 6 days of exposure**
- When IG 0.25 mL/kg is given, wait 5 months before vaccinating with MMR or other live viral vaccines. If IG 0.5 mL/kg given, wait 6 months.
- Measles vaccine contraindications and precautions (see vaccine information sheet for complete details):
 - Severe allergic reaction to MMR or vaccine component (gelatin, neomycin)
 - Pregnancy (pregnancy should be avoided for 4 weeks following MMR)
 - Severe immunosuppression (but HIV infection is not a contraindication unless there is evidence of severe immunosuppression)
 - E.g., HIV+ adults with CD4+ T-cells <200
 - Persons receiving large daily doses of corticosteroids (>2 mg/kg/day or >20 mg/day of prednisone) for at least 14 days
 - Persons with moderate to severe acute illness should not be vaccinated until the illness has resolved
 - Receipt of antibody containing blood products (e.g., IG) will interfere with seroconversion to vaccine
 - History of thrombocytopenia

Outbreak Control

Measles outbreaks can be costly and widespread. The key to control is a prompt public health response to identify and ensure vaccination of contacts.

Immediately report any suspect case of measles, to your local health department or Arizona Department of Health Services at (602) 364-4562.

For additional information about measles

CDC website: <http://www.cdc.gov/vaccines/vpd-vac/measles/default.htm>

ADHS website: http://www.azdhs.gov/phs/oids/topics_h_z.htm#M

Updated 2/25/2008